Kerriamycin A is a natural antibiotic compound that belongs to the class of macrolides, characterized by a large lactone ring structure. It is produced by certain strains of the bacterium *Micromonospora* and exhibits notable antibacterial activity, particularly against Gram-positive bacteria. The compound is known for its unique structural features, including multiple hydroxyl groups and a distinctive sugar moiety, which contribute to its biological activity. Kerriamycin A has garnered interest in pharmaceutical research due to its potential applications in treating bacterial infections and its role in the development of new antimicrobial agents. Its mechanism of action typically involves inhibition of protein synthesis in susceptible bacteria, making it a valuable subject of study in the field of medicinal chemistry. Additionally, the compound's stability, solubility, and pharmacokinetic properties are important factors that influence its therapeutic efficacy and potential side effects. As research continues, kerriamycin A may provide insights into the development of novel antibiotics in an era of increasing antibiotic resistance.

kerriamycin A

98474-20-5: Kerriamycin A is a natural antibiotic compound that belongs to the class of macrolides, characterized by a large lactone ring structure. It is produced by certain strains of the bacterium *Micromonospora* and exhibits notable antibacterial activity, particularly against Gram-positive bacteria. The compound is known for its unique structural features, including multiple hydroxyl groups and a distinctive sugar moiety, which contribute to its biological activity. Kerriamycin A has garnered interest in pharmaceutical research due to its potential applications in treating bacterial infections and its role in the development of new antimicrobial agents. Its mechanism of action typically involves inhibition of protein synthesis in susceptible bacteria, making it a valuable subject of study in the field of medicinal chemistry. Additionally, the compound's stability, solubility, and pharmacokinetic properties are important factors that influence its therapeutic efficacy and potential side effects. As research continues, kerriamycin A may provide insights into the development of novel antibiotics in an era of increasing antibiotic resistance.

<p>Kerriamycin A exhibits antibacterial activity against Gram-positive bacteria and also has the capability to inhibit Ehrlich ascites carcinoma.</p>

CAS 98474-20-5

kerriamycin A

Kerriamycin A

Ref: TM-TN10013